Efficacy and Safety of Prothrombin complex Concentrate in Patients with Massive Intraoperative Bleeding During non-Cardiac Surgery: A Retrospective Cohort Study.

Abstract

PurposeThe efficacy and safety of four-factor prothrombin complex concentrate (4F-PCC) in managing bleeding during non-cardiac surgery are unclear. We investigated the associations of 4F-PCC with postoperative RBC transfusion and adverse events in non-cardiac surgery patients with massive intraoperative bleeding.MethodsThis retrospective cohort study consecutively included non-cardiac surgery patients with massive intraoperative bleeding at a tertiary hospital (2014-2020). Administration of 4F-PCC was categorized into dose groups based on quartiles: 0 (reference), 2.8-6.7, 6.7-11.5, 11.5-19.4, and 19.4-87.5 IU/kg. Outcomes included postoperative RBC transfusion, major thromboembolic events, severe acute kidney injury, and lengths of ICU and hospital stay.ResultsOf 137 patients, 89 (65.0%) received 4F-PCC. The 6.7-11.5 IU/kg group were significantly associated with reduced postoperative RBC transfusion compared to the non-4F-PCC group (adjusted mean difference, -1.29 units; 95%CI, -2.55 to -0.04 units, P = 0.044). Such findings were not observed in other dose groups. Notably, the benefits were particularly significant in patients with preoperative platelet count ≥150 × 109/l (P = 0.031), and fibrinogen ≥3 g/l (P = 0.025). The 6.7-11.5 IU/kg group exhibited comparable incidences of major thromboembolic events (13.0% vs 10.4%) and severe acute kidney injury (8.7% vs 8.3%) compared to the non-4F-PCC group. The lengths of ICU and hospital stay were similar across groups.Conclusion4F-PCC may be associated with decreased postoperative RBC transfusion in non-cardiac surgery patients experiencing massive intraoperative bleeding, without a significant increase in the risk of major thromboembolic events. Randomized trials with stratified dosing are warranted to confirm efficacy, safety, and determine optimal doses.Clinical Trial NumberChiCTR2500096573.